Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Zai Lab Ltd.

Incyte Corp.  said Tuesday it will receive an upfront payment of $17.5 million as part of a license agreement with Zai Lab Ltd.

Incyte enters license pact with Zai Lab to commercialize its cancer treatment in Greater China

Blueprint Medicines

uniQure

Verastem

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

AGCO

Baxter

Cornerstone Ondemand

Discovery

Federal Realty Investment Trust

Whirlpool

Incyte, Whirlpool and Baxter are just some of the stocks to buy here as a means of shrugging off the summer's looming lethargy.

7 Hot Stocks to Buy for a Seemingly Sleepy Summer

Iovance Biotherapeutics

Cancer therapy stocks rallied after Pfizer made a deal to boost its oncology offerings. These industry players may also be takeover targets.

Cancer Therapy Stocks Soar After Pfizer Deal

Affimed

Arrowhead Pharmaceuticals

Recro Pharma

Repligen

Veracyte

Vertex Pharmaceuticals

Despite the trade dispute with China, these biotech stocks each earn top marks in Portfolio Grader for fundamentals, earnings and momentum.

7 Top-Rated Biotech Stocks to Invest In Today

Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.

Incyte Begins Phase III Study for Treatment of Duct Cancer

Acorda Therapeutics

Mesoblast

Mesoblast (MESO) begins the rolling submission of a BLA for its lead product, candidate remestemcel-L, to the FDA for treating children with steroid-refractory acute graft versus host disease.

Mesoblast Starts Rolling BLA Submission for Remestemcel-L

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Why Is Incyte (INCY) Down 1.7% Since Last Earnings Report?

Incyte (INCY) obtains FDA approval for a third indication of lead drug, Jakafi, for the treatment of GVHD.

Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi

Investors braced for bad earnings news from the biotech specialist, but Incyte surpassed those expectations late in the month.

Why Incyte Stock Lost 11% in April

Incyte Corporation (INCY) CEO Hervé Hoppenot on Q1 2019 Results - Earnings Call Transcript

While Incyte's (INCY) earnings and revenues beat estimates in Q1, Jakafi sales fall short of the same.

Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y

Incyte earnings and revenue easily cleared first-quarter estimates. Shares of the biotech rose slightly early Tuesday.

Incyte Earnings, Sales Easily Beat Views

Incyte (INCY) is slated to report first-quarter results on Apr 30. Investors will primarily focus on Jakafi sales and pipeline updates.

Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings?

Incyte's biggest moneymaker, a cancer treatment called Jakafi, could grow by double digits in the first quarter, an analyst said Monday as he maintained a strong-buy rating on Incyte stock.

Why Novartis Earnings Provided A Bullish Signal For This Biotech Stock

Cigna

Columbia Sportswear Company

CommScope Hld

Synopsys

It will be prudent to invest in stocks that are part of the S&P 500 or Nasdaq Composite. We have narrowed down our search to five such companies.

Can S&P 500 and Nasdaq Sustain Record Run? 5 Top Picks

Ceridian HCM Holding Inc.

Cabot Oil & Gas

Snap

The recently released three major economic data of March clearly indicated that the inherent strength of the economy remains intact.

5 Must-Buy Stocks Amid Exaggerated Economic Slowdown

Incyte is a large-cap pharmaceutical company. Most of its revenue is derived from a single drug, Jakafi.

Incyte Value Will Remain Highly Dependent On Jakafi Sales In 2019

News for Incyte Stock (INCY)